SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment o… Read more
SQZ Biotechnologies Company (SQZB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: -7.726x
Based on the latest financial reports, SQZ Biotechnologies Company (SQZB) has a cash flow conversion efficiency ratio of -7.726x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.53 Million) by net assets ($1.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SQZ Biotechnologies Company - Cash Flow Conversion Efficiency Trend (2018–2022)
This chart illustrates how SQZ Biotechnologies Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SQZ Biotechnologies Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SQZ Biotechnologies Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arqit Quantum Inc. Warrants
NASDAQ:ARQQW
|
-0.603x |
|
Equity Story Group Ltd
AU:EQS
|
0.833x |
|
Rover Metals Corp
OTCQB:ROVMF
|
-0.025x |
|
WAYSIDE TECH GRP
MU:PYA
|
-0.041x |
|
Astron Paper & Board Mill Limited
NSE:ASTRON
|
0.079x |
|
Hui Srl
VI:HUI
|
N/A |
|
KELLOGG - Dusseldorf Stock Exchang
DU:KEL
|
0.147x |
|
ESTEE LAUDER-A - Dusseldorf Stock Exchang
DU:ELAA
|
-0.132x |
Annual Cash Flow Conversion Efficiency for SQZ Biotechnologies Company (2018–2022)
The table below shows the annual cash flow conversion efficiency of SQZ Biotechnologies Company from 2018 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $57.15 Million | $-83.55 Million | -1.462x | -120.67% |
| 2021-12-31 | $123.98 Million | $-82.14 Million | -0.663x | -95.30% |
| 2020-12-31 | $127.20 Million | $-43.15 Million | -0.339x | +40.65% |
| 2019-12-31 | $58.59 Million | $-33.49 Million | -0.572x | -270.31% |
| 2018-12-31 | $62.86 Million | $21.10 Million | 0.336x | -- |